Medpace Holdings, Inc. $MEDP Shares Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 30.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,713 shares of the company’s stock after acquiring an additional 2,481 shares during the period. Jefferies Financial Group Inc.’s holdings in Medpace were worth $6,017,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Optiver Holding B.V. acquired a new position in Medpace during the 3rd quarter worth $27,000. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace in the 4th quarter valued at about $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace in the 4th quarter valued at about $30,000. Quarry LP acquired a new position in shares of Medpace in the 3rd quarter valued at about $35,000. Finally, Root Financial Partners LLC acquired a new position in shares of Medpace in the 3rd quarter valued at about $38,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on MEDP shares. Truist Financial decreased their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday, February 11th. Royal Bank Of Canada decreased their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and decreased their price target for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Finally, Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research report on Friday, February 13th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $467.08.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $432.80 on Tuesday. Medpace Holdings, Inc. has a one year low of $287.17 and a one year high of $628.92. The company has a 50 day moving average of $458.70 and a 200-day moving average of $517.79. The stock has a market cap of $12.36 billion, a price-to-earnings ratio of 27.20, a P/E/G ratio of 2.20 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the previous year, the company earned $3.67 earnings per share. The business’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Insiders Place Their Bets

In related news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.